SRTSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Sensus Healthcare, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$2.76−0.01 (-0.36%)
Close on Oct 19, 2026
- Market cap
- $45.44M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2014 to 2025
Gross margin
43.2%−11.6 pts over 5 years
Operating margin
-37.5%+48.5 pts over 5 years
Net margin
-28.1%+43.3 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -34.3% | -14.9% | +23.5% | +10.3% | |
| Gross profit | -51.4% | -26.3% | +17.7% | +6.1% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -3.3% | -27.6% | -14.9% | |
| Return on assets | -2.4% | -21.1% | -13.4% | |
| Current ratio | 4.58 | 5.18 | 9.72 | |
| Interest coverage | -16.6× | -588.1× | – | |
| Inventory turnover | 4.4× | 1.2× | 1.3× | |
| Capex to revenue | 1.9% | 3.7% | 0.7% | |
| Diluted shares | 12M | 16M | 16M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Sensus Healthcare generated $5.20M from operations and spent $4.31M on capital expenditure, dividends and share buybacks. 23% of that went back into the business.
Generated
$5.20M
Used
$4.31M
Capital expenditure$988.00K23%Dividends$00%Share buybacks$3.33M77%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-28.1%
×Asset turnover0.48×
×Equity multiplier1.11×
=Return on equity, FY2025-14.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -28.1% | 0.48× | 1.11× | -14.9% |
| FY2024 | 15.9% | 0.72× | 1.11× | 12.7% |
| FY2023 | 2.0% | 0.44× | 1.14× | 1.0% |
| FY2022 | 54.4% | 1.00× | 1.20× | 65.5% |
| FY2021 | 15.2% | 0.90× | 1.27× | 17.3% |
| FY2020 | -71.4% | 0.29× | 1.31× | -27.6% |
| FY2019 | -6.2% | 0.78× | 1.29× | -6.2% |
| FY2018 | -7.7% | 1.01× | 1.37× | -10.6% |
| FY2017 | -18.0% | 1.09× | 1.40× | -27.5% |
| FY2016 | -2.3% | 1.04× | 1.35× | -3.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$7.72M
- Cash generatingOperating cash flow above zero$528.00K
- Return on assets improvedROA up on the prior year12.4% → -12.4%
- Earnings backed by cashOperating cash flow above net income$528.00K vs -$7.72M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose9.64 → 9.72
- No dilutionShare count did not rise16M → 16M
- Gross margin improvedGross margin up on the prior year58.44% → 43.18%
- More efficientAsset turnover rose0.78 → 0.44